-
AZ, Sanofi, and Pfizer all adjust!
Time of Update: 2022-01-21
Omni-channel business department follows the trend Among the above-mentioned changes, the “Internet celebrity” pharmaceutical company AstraZeneca has received the most attention when it established an omni-channel business unit .
-
30 newly listed drugs are quickly listed on the Internet through the "green channel"!
Time of Update: 2022-01-21
According to the data, it is expected that in 2021, the R&D investment of Hengrui, Qilu and CSPC will reach a new high, with a total of more than 10 billion yuan .
-
Announcement of the registration number of oral collapse accessories and summary of Dongchen registration number
Time of Update: 2022-01-21
This excipient is named Topfiller-OD™ mannitol microcrystalline interpolymerized calcium co-processing product, model TMF965, registration number F20210000478 .
TMF Series Models Dongchen Pharmaceutical Registration Number Summary sample applicationDongchen microcrystalline cellulose and co-processing products Identify the QR code to fill in your requirements and apply for the required samples for free
-
Junshi Bio and AstraZeneca "break up", is it time for local innovative drugs to be self-operated?
Time of Update: 2022-01-21
As a leading enterprise in China's new generation of Biotech, Junshi Biotech has covered five major disease fields including tumor, chronic metabolism, autoimmunity, anti-infection and nervous system through the method of "independent research and development + cooperative introduction" for many years, involving monoclonal antibody, dual The breadth and depth of the 45 pipelines in the drug forms such as antibodies, ADCs, and peptides are not inferior to those of Big Pharma.
-
Announcement on the draft standard of glacial acetic acid medicinal excipients
Time of Update: 2022-01-21
Announcement on the draft standard of glacial acetic acid medicinal excipients Source: State Pharmacopoeia Commission Time: 2022-01-05 14:23: 52Print No.
: Fg2021-0470 Our committee plans to revise the standards for glacial acetic acid excipients.
-
Over 80% of pharmaceutical companies have a good year's performance forecast!
Time of Update: 2022-01-21
Among them, more than 80% of the pharmaceutical companies have positive results, but the sub-sectors of the industry are significantly differentiated, and companies in the traditional Chinese medicine and in vitro testing industries have performed better .
-
8 departments jointly issued the "14th Five-Year Plan" National Drug Safety and Promotion of High-quality Development Plan
Time of Update: 2022-01-21
It was learned on December 30 that a few days ago, the State Food and Drug Administration and other 8 departments jointly issued the "14th Five-Year Plan for National Drug Safety and Promotion of Hi
-
The benefits of traditional Chinese medicine innovation are coming one after another!
Time of Update: 2022-01-21
Highlight the key role of human experience The "Opinions of the Central Committee of the Communist Party of China and the State Council on Promoting the Inheritance, Innovation and Development of Traditional Chinese Medicine" issued in October 2019 put forward the requirements of the "three-in-one" review evidence system .
-
Heavy document release!
Time of Update: 2022-01-21
In addition, medical representatives shall not carry out business activities in violation of laws and regulations, and shall not give kickbacks to medical institution staff (including their close relatives and other specific related persons) in any name or form .
-
In 2021, 83 new drugs will be approved, 19 will be included in medical insurance, and Roche and BeiGene will be the first in the number of approvals
Time of Update: 2022-01-21
On June 23, Fosun Kite's akirenxe injection was approved for marketing for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after receiving second-line or above systemic therapy .
-
Another batch of pharmaceutical companies passed the consistency evaluation!
Time of Update: 2022-01-21
Tai Chi Group - Allergy Drug Consistency Evaluation Tai Chi Group announced that Southwest Pharmaceuticals, a subsidiary of the company, recently received the "Approval Notice for Supplementary Drug Application" from the State Food and Drug Administration, and its declared "Promethazine Hydrochloride Tablets" (dosage form) : tablet; specification: 12.
-
How are the tens of billions of dollars in "snake swallowing elephant" pharmaceutical companies developing?
Time of Update: 2022-01-21
For example, Takeda Pharmaceutical announced the acquisition of the British pharmaceutical company Shire for $62 billion; Gene; due to the imminent expiry of the blockbuster product "Humei Le", AbbVie spent US$64.
Recently, Bristol-Myers Squibb expects revenue of about $47 billion in 2022 .
-
The development of the Chinese medicine industry has accelerated significantly, and the number of new Chinese medicines approved will continue to grow
Time of Update: 2022-01-21
According to the data, among the 1,439 domestic Class 1 innovative drug registration applications accepted by CDE in 2021, the number of Chinese medicine applications has reached a new high .
-
Icariin Soft Capsules (Acoradine) Approved for Marketing
Time of Update: 2022-01-21
If there is any copyright infringement, please contact the Secretariat of the Large Variety Alliance of Traditional Chinese Medicine, and we will reply in time .
-
Shanghai Anbisheng Pharmaceutical won the first batch of "Zhangjiang Star"
Time of Update: 2022-01-21
In recent years, Shanghai Ambison Pharmaceuticals has continuously increased investment in research and development, and successfully launched 10 self-owned products in China and the United States.
-
CDE issues 11 guidelines covering clinical trials, chemical generics, etc.
Time of Update: 2022-01-21
68) In order to encourage the research and development of new drugs, under the deployment of the State Drug Administration, the Center for Drug Evaluation organized and formulated the "Guidelines for Writing a "Clinical Risk Management Plan" (for Trial Implementation)" (see attachment) .
-
Which product is the hottest product on the new crown track is expected to become a blockbuster?
Time of Update: 2022-01-15
Vaccines: 25 companies compete for a market of 100 billion yuanDomestic pharmaceutical companies have developed five technical routes of new crown vaccines in five ways, from the most traditional inactivated vaccines (represented by Kexing and Sinopharm), to adenovirus vaccines (such as AstraZeneca and Johnson & Johnson), and attenuated influenza viruses Vector vaccines, recombinant protein vaccines (such as Zhifei, Taiwan High-end, United Asia), and the latest technology mRNA vaccines (such as BNT162b2 and Modena) .
-
Shangjian Bio-CD38/CD47 double antibody was approved for clinical use in the U.S.
Time of Update: 2022-01-15
It is worth mentioning that, based on the BIMA double antibody platform, Sunkin Bio has also developed a number of "1+1>2" double antibody projects, two of which have been approved for clinical use .
-
Targeting CLDN 18.2!
Time of Update: 2022-01-15
According to the press release of Keji Pharmaceuticals, CT041 has been approved by the US FDA, China National Medical Products Administration (NMPA) and Health Canada to conduct clinical trials .
Reference materials:[1] The Canadian clinical trial of CT041, a CAR-T product independently developed by Keji Pharmaceuticals, was approved.
-
100 million yuan down payment!
Time of Update: 2022-01-15
, a wholly-owned subsidiary of CSPC (Hereinafter referred to as "Shiyao") Exclusively authorized development and commercialization of Connoa's innovative drug CM326 (a recombinant humanized monoclonal antibody against TSLP) in moderate to severe asthma and chronic obstructive pulmonary disease (COPD) and other respiratory diseases Sign the agreement formally .
